Ito Shin, Hatazaki Kyoko, Shimuta Ken, Kondo Hiromi, Mizutani Kosuke, Yasuda Mitsuru, Nakane Keita, Tsuchiya Tomohiro, Yokoi Shigeaki, Nakano Masahiro, Ohinishi Makoto, Deguchi Takashi
From the *iClinic, 5-9-6 Nagamachi, Taihaku-ku, Sendai, Miyagi; †Department of Urology, Graduate School of Medicine, Gifu University, Gifu City, Gifu; and ‡Department of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Sex Transm Dis. 2017 Apr;44(4):205-210. doi: 10.1097/OLQ.0000000000000573.
There have been few comprehensive studies on Haemophilus influenza-positive urethritis.
In this retrospective study, we enrolled 68 men with H. influenzae-positive urethritis, including coinfections with Neisseria gonorrhoeae, Chlamydia trachomatis, and/or genital mycoplasmas: 2, 3, 20, and 43 treated with ceftriaxone, levofloxacin, sitafloxacin, and extended-release azithromycin (azithromycin-SR), respectively. We assessed microbiological outcomes in 54 men and clinical outcomes in 46 with H. influenzae-positive monomicrobial nongonococcal urethritis. We determined minimum inhibitory concentrations (MICs) of 6 antimicrobial agents for 59 pretreatment isolates.
H. influenzae was eradicated from the men treated with ceftriaxone, levofloxacin, or sitafloxacin. The eradication rate with azithromycin-SR was 85.3%. The disappearance or alleviation of urethritis symptoms and the decreases in leukocyte counts in first-voided urine were significantly associated with the eradication of H. influenzae after treatment. For the isolates, ceftriaxone, levofloxacin, sitafloxacin, azithromycin, tetracycline, and doxycycline MICs were ≤0.008-0.25, 0.008-0.5, 0.001-0.008, 0.12-1, 0.25-16, and 0.25-2 μg/mL, respectively. The azithromycin MICs for 3 of 4 strains persisting after azithromycin-SR administration were 1 μg/mL. H. influenzae with an azithromycin MIC of 1 μg/mL increased chronologically.
H. influenzae showed good responses to the chemotherapies for urethritis. The significant associations of the clinical outcomes of the chemotherapies with their microbiological outcomes suggested that H. influenzae could play pathogenic roles in urethritis. All isolates, except for one with decreased susceptibility to tetracyclines, were susceptible to the examined agents. However, the increase in H. influenzae with an azithromycin MIC of 1 μg/mL might threaten efficacies of azithromycin regimens on H. influenzae-positive urethritis.
关于流感嗜血杆菌阳性尿道炎的综合研究较少。
在这项回顾性研究中,我们纳入了68例流感嗜血杆菌阳性尿道炎男性患者,包括合并淋病奈瑟菌、沙眼衣原体和/或生殖支原体感染的患者:分别有2例、3例、20例和43例接受了头孢曲松、左氧氟沙星、司帕沙星和缓释阿奇霉素(阿奇霉素-SR)治疗。我们评估了54例患者的微生物学结果以及46例流感嗜血杆菌阳性单一微生物非淋菌性尿道炎患者的临床结果。我们测定了59株治疗前分离株对6种抗菌药物的最低抑菌浓度(MIC)。
接受头孢曲松、左氧氟沙星或司帕沙星治疗的男性患者中,流感嗜血杆菌被根除。阿奇霉素-SR的根除率为85.3%。治疗后尿道炎症状的消失或减轻以及首次晨尿中白细胞计数的下降与流感嗜血杆菌的根除显著相关。对于分离株,头孢曲松、左氧氟沙星、司帕沙星、阿奇霉素、四环素和多西环素的MIC分别≤0.008 - 0.25、0.008 - 0.5、0.001 - 0.008、0.12 - 1、0.25 - 16和0.25 - 2 μg/mL。阿奇霉素-SR给药后仍持续存在的4株菌株中有3株的阿奇霉素MIC为1 μg/mL。阿奇霉素MIC为1 μg/mL的流感嗜血杆菌随时间推移有所增加。
流感嗜血杆菌对尿道炎化疗表现出良好反应。化疗的临床结果与其微生物学结果之间的显著关联表明,流感嗜血杆菌可能在尿道炎中起致病作用。除1株对四环素敏感性降低的菌株外,所有分离株对所检测药物均敏感。然而,阿奇霉素MIC为1 μg/mL的流感嗜血杆菌数量增加可能会威胁阿奇霉素方案对流感嗜血杆菌阳性尿道炎的疗效。